CN105025895B - 用于治疗肺动脉高压和肺损伤的1,3-二氢咪唑-2-硫酮衍生物 - Google Patents

用于治疗肺动脉高压和肺损伤的1,3-二氢咪唑-2-硫酮衍生物 Download PDF

Info

Publication number
CN105025895B
CN105025895B CN201380059547.2A CN201380059547A CN105025895B CN 105025895 B CN105025895 B CN 105025895B CN 201380059547 A CN201380059547 A CN 201380059547A CN 105025895 B CN105025895 B CN 105025895B
Authority
CN
China
Prior art keywords
compound
ethyl
base
thioketones
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380059547.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN105025895A (zh
Inventor
帕特里西奥·曼纽尔·维埃拉·阿尔奥桥·苏亚雷斯·达·席尔瓦
玛丽亚·乔奥·马塞多·达·席尔瓦·博尼法希尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bial Portela and Cia SA
Original Assignee
Bial Portela and Cia SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Portela and Cia SA filed Critical Bial Portela and Cia SA
Publication of CN105025895A publication Critical patent/CN105025895A/zh
Application granted granted Critical
Publication of CN105025895B publication Critical patent/CN105025895B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380059547.2A 2012-11-14 2013-11-14 用于治疗肺动脉高压和肺损伤的1,3-二氢咪唑-2-硫酮衍生物 Expired - Fee Related CN105025895B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261726119P 2012-11-14 2012-11-14
US61/726,119 2012-11-14
PCT/PT2013/000065 WO2014077715A1 (en) 2012-11-14 2013-11-14 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury

Publications (2)

Publication Number Publication Date
CN105025895A CN105025895A (zh) 2015-11-04
CN105025895B true CN105025895B (zh) 2019-02-26

Family

ID=49759506

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380059547.2A Expired - Fee Related CN105025895B (zh) 2012-11-14 2013-11-14 用于治疗肺动脉高压和肺损伤的1,3-二氢咪唑-2-硫酮衍生物

Country Status (23)

Country Link
US (3) US9604970B2 (cg-RX-API-DMAC7.html)
EP (1) EP2919780B1 (cg-RX-API-DMAC7.html)
JP (1) JP6373275B2 (cg-RX-API-DMAC7.html)
KR (1) KR102259938B1 (cg-RX-API-DMAC7.html)
CN (1) CN105025895B (cg-RX-API-DMAC7.html)
AU (1) AU2013345494B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015010969B1 (cg-RX-API-DMAC7.html)
CA (1) CA2890920C (cg-RX-API-DMAC7.html)
CY (1) CY1120953T1 (cg-RX-API-DMAC7.html)
DK (1) DK2919780T3 (cg-RX-API-DMAC7.html)
ES (1) ES2693025T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20181651T1 (cg-RX-API-DMAC7.html)
IN (1) IN2015DN04089A (cg-RX-API-DMAC7.html)
LT (1) LT2919780T (cg-RX-API-DMAC7.html)
MX (1) MX355422B (cg-RX-API-DMAC7.html)
PL (1) PL2919780T3 (cg-RX-API-DMAC7.html)
PT (1) PT2919780T (cg-RX-API-DMAC7.html)
RS (1) RS57874B1 (cg-RX-API-DMAC7.html)
RU (1) RU2718055C2 (cg-RX-API-DMAC7.html)
SI (1) SI2919780T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800560T1 (cg-RX-API-DMAC7.html)
TR (1) TR201815850T4 (cg-RX-API-DMAC7.html)
WO (1) WO2014077715A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2015DN04089A (cg-RX-API-DMAC7.html) 2012-11-14 2015-10-09 BIAL PORTELA & Cª S A
GB201810395D0 (en) * 2018-06-25 2018-08-08 Bial Portela & Ca Sa Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation
WO2021005623A1 (en) * 2019-07-08 2021-01-14 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera
CN118598820B (zh) * 2024-02-06 2025-07-08 石家庄四药有限公司 一种二苯基三嗪类化合物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081232A1 (en) * 2006-01-13 2007-07-19 Bial- Portela & Ca, S.A. Drug combinations
WO2008136695A1 (en) * 2007-05-08 2008-11-13 Portela & Ca, S.A. 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623107B2 (ja) * 1990-11-16 1994-03-30 帝人株式会社 プロスタサイクリン類を有効成分とする薬学的組成物
HUT76295A (en) * 1994-04-26 1997-07-28 Syntex Inc Imidazolyl- and triazolyl-thion derivatives, pharmaceutical compositions containing them and process for producing them
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US7125904B2 (en) * 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
US20040102361A1 (en) * 2002-11-27 2004-05-27 Frederic Bodin Pharmaceutical composition for the treatment of pulmonary arterial hypertension
GB0610804D0 (en) * 2006-05-31 2006-07-12 Portela & Ca Sa New crystal forms
GB0700635D0 (en) * 2007-01-12 2007-02-21 Portela & Ca Sa Therapy
US20100166869A1 (en) * 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
EP2231648A1 (en) * 2007-12-05 2010-09-29 BIAL - Portela & Ca., S.A. New salts and crystal forms
JP2011508775A (ja) * 2008-01-03 2011-03-17 ビオマリン プハルマセウトイカル インコーポレイテッド Ｂｈ４応答性状態を治療するためのプテリン類似体
AR070841A1 (es) * 2008-03-13 2010-05-05 Bial Portela & Ca Sa Proceso de hidrogenacion catalitica asimetrica
AR071632A1 (es) * 2008-05-06 2010-06-30 Bial Portela & Ca Sa Proceso catalitico para hidrogenacion asimetrica en la sintesis de inhibidores de la dopamina-beta-hidroxilasa"
DE102008054205A1 (de) * 2008-10-31 2010-05-06 Bayer Schering Pharma Aktiengesellschaft Verwendung von Helium-Sauerstoff-Gasgemischen zur Behandlung der pulmonalen arteriellen Hypertonie
RU2604734C2 (ru) * 2010-12-22 2016-12-10 БИАЛ-ПОРТЕЛА энд КА., С.А. Кристаллическая форма и способ ее очистки
IN2015DN04089A (cg-RX-API-DMAC7.html) 2012-11-14 2015-10-09 BIAL PORTELA & Cª S A

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081232A1 (en) * 2006-01-13 2007-07-19 Bial- Portela & Ca, S.A. Drug combinations
WO2008136695A1 (en) * 2007-05-08 2008-11-13 Portela & Ca, S.A. 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase

Also Published As

Publication number Publication date
EP2919780B1 (en) 2018-08-01
MX2015005910A (es) 2015-08-10
CY1120953T1 (el) 2020-05-29
BR112015010969B1 (pt) 2020-05-26
AU2013345494B2 (en) 2018-03-22
IN2015DN04089A (cg-RX-API-DMAC7.html) 2015-10-09
HRP20181651T1 (hr) 2018-12-14
US10308640B2 (en) 2019-06-04
MX355422B (es) 2018-04-18
CN105025895A (zh) 2015-11-04
US20190241545A1 (en) 2019-08-08
RU2015120164A (ru) 2017-01-10
SI2919780T1 (sl) 2018-12-31
DK2919780T3 (en) 2018-11-26
EP2919780A1 (en) 2015-09-23
TR201815850T4 (tr) 2018-11-21
PT2919780T (pt) 2018-11-13
RU2718055C2 (ru) 2020-03-30
JP6373275B2 (ja) 2018-08-15
WO2014077715A1 (en) 2014-05-22
CA2890920C (en) 2020-12-15
KR20150084022A (ko) 2015-07-21
JP2016504286A (ja) 2016-02-12
ES2693025T3 (es) 2018-12-07
SMT201800560T1 (it) 2019-01-11
BR112015010969A2 (pt) 2017-08-22
HK1215393A1 (en) 2016-08-26
RS57874B1 (sr) 2018-12-31
AU2013345494A1 (en) 2015-05-14
KR102259938B1 (ko) 2021-06-03
US20170369477A1 (en) 2017-12-28
US20150299172A1 (en) 2015-10-22
LT2919780T (lt) 2018-11-12
CA2890920A1 (en) 2014-05-22
PL2919780T3 (pl) 2019-01-31
US9604970B2 (en) 2017-03-28

Similar Documents

Publication Publication Date Title
US20180161314A1 (en) Methods for Treating Hyperuricemia and Related Diseases
CA2867174C (en) Treatment of cancer with tor kinase inhibitors
EA012600B1 (ru) Применение антагониста рецептора ангиотензина ii телмисартана для повышения чувствительности к инсулину
TW201924685A (zh) 用於治療內皮素相關疾病之4-嘧啶磺醯胺衍生物與sglt-2抑制劑之組合
CN105025895B (zh) 用于治疗肺动脉高压和肺损伤的1,3-二氢咪唑-2-硫酮衍生物
Son et al. Pharmacokinetic interaction between rosuvastatin, telmisartan, and amlodipine in healthy male Korean subjects: a randomized, open-label, multiple-dose, 2-period crossover study
ES2934846T3 (es) Inhibidores de CDK para tratamiento de PAH
AU2009225323B2 (en) Pyridylsulfonamido pyrimidines for treating diabetic nephropathy
AU2006241806B2 (en) Agent for prophylaxis and treating pancreatitis
US20210346366A1 (en) Ch24h inhibitors for pain use
CN102796093B (zh) 含硫代吗啉的吡咯衍生物、其制备方法和用途
WO2025229051A1 (en) Use of atr inhibitors in combination with antiandrogen agent
JP2958678B2 (ja) 一過性脳虚血発作抑制剤
EA047563B1 (ru) Канаглифлозин для лечения больных диабетом пациентов с хроническим заболеванием почек
HK1215393B (en) 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury
EA045981B1 (ru) Комбинация 4-пиримидинсульфамидного производного с ингибитором sglt-2 для лечения заболеваний, связанных с эндотелином
JPH11240834A (ja) 一過性脳虚血発作抑制剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190226